Imfinzi snags another FDA nod to treat lung cancer, this time for limited-stage SCLCnews2024-12-05T19:29:03+00:00December 5th, 2024|Endpoints News|
Biosecure compromise could add review process for named companies, sources saynews2024-12-05T19:18:15+00:00December 5th, 2024|Endpoints News|
Moderna defends pandemic prep as vaccine skeptics gain powernews2024-12-04T19:45:27+00:00December 4th, 2024|Endpoints News|
Trade group tells FDA that semaglutide is not too ‘complex’ for compoundingnews2024-12-04T19:38:18+00:00December 4th, 2024|Endpoints News|
Sickle cell gene therapies included in new Medicaid access modelnews2024-12-04T17:46:55+00:00December 4th, 2024|Endpoints News|
Lilly removes body mass ranges from FDA label for weight loss drugnews2024-12-03T20:30:12+00:00December 3rd, 2024|Endpoints News|
Eli Lilly, Pfizer stress independence of telehealth partners in response to senatorsnews2024-12-03T19:40:36+00:00December 3rd, 2024|Endpoints News|
Applied Therapeutics gets FDA warning letter for rare disease drugnews2024-12-03T18:59:26+00:00December 3rd, 2024|Endpoints News|
FDA defends increased use of guidance in new report to Congressnews2024-12-02T19:40:20+00:00December 2nd, 2024|Endpoints News|
J&J looks to expand Tremfya in two pediatric indicationsnews2024-12-02T18:34:00+00:00December 2nd, 2024|Endpoints News|
